Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C

Journal of Gastroenterology

Volumn 39, Issue 11, 2004, Pages 1106-1109

  Kasahara, Akinori ^a   Hiraide, Atsushi ^a   Tomita, Naruya ^a   Iwahashi, Hiromi ^b   Imagawa, Akihisa ^b   Ohguro, Nobuyuki ^b   Yamamoto, Shuji ^b   Mita, Eiji ^c   Hayashi, Norio ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

Author keywords

Interferon, chronic hepatitis C; Vogt Koyanagi Harada disease

Indexed keywords

ALPHA INTERFERON; INSULIN; METHYLPREDNISOLONE; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; CASE REPORT; DIABETES MELLITUS; DIET RESTRICTION; EYE DISEASE; HEADACHE; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; IMMUNOMODULATION; LABORATORY TEST; MALE; MUSCLE STIFFNESS; PAPILLEDEMA; PATIENT MONITORING; PERIODIC MEDICAL EXAMINATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETINA EDEMA; SKIN PIGMENTATION; UVEITIS; VISUAL IMPAIRMENT; VISUAL SYSTEM EXAMINATION; VOGT KOYANAGI SYNDROME;

ADULT; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; SKIN PIGMENTATION; TIME FACTORS; UVEOMENINGOENCEPHALITIC SYNDROME;

EID: 10244250468     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-004-1452-4     Document Type: Article

References (28)

1. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.
2. Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995;132:587-93.
3. Marcellin P, Pouteau M, Renard P, Grynblat J-M, Colas Linhart N, Bardet P, et al. Sustained hypothyroidism induced by recombinant α interferon in patients with chronic hepatitis C. Gut 1992;33:855-6.
4. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91.
5. Kawano T, Shigehira M, Uto H, Nakama T, Kato J, Hayashi K, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996;91:309-13.
6. Guyer DR, Tiedeman J, Yannuzzi LA, Slakter JS, Parkr D, Kelley JT, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993;111:350-6.
7. Sylvestre DL, Disson AR, Bui DP. Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy. J Viral Hepatitis 2003;10:467-70.
8. Ohno S, Devron HC, Kimura SJ, O'Connor GR. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 1977;83:735-40.
9. Sugita S, Sagawa K, Mochizuki M, Shichijo S, Itoh K. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease. Int Immunol 1996;8:799-803.
10. Norose K, Yano A. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. Br J Ophthalmol 1996;80:1002-8.
11. Read RW, Rao NA, Cunningham ET. Vogt-Koyanagi-Harada disease. Curr Opin Ophthalmol 2000;11:437-42.
12. Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol 1991;109:682-7.
13. Gocho K, Kondo I, Yamaki K. Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 2001;42:2004-9.
14. Sakamoto T, Murata T, Inomata H. Class II major histocompatibility complex on melanocytes of Vogt-Koyanagi-Harada disease. Arch Ophthalmol 1991;109:1270-4.
15. Inomata H, Sakamoto T. Immunohistochemical studies of Vogt-Koyanagi-Harada disease with sunset sky fundus. Curr Eye Res 1990;9(Suppl): 35-40.
16. Okada T, Sakamoto T, Ishibashi T, Inomata H. Vitiligo in Vogt-Koyanagi-Harada disease: Immunohistological analysis of inflammatory site. Graefes Arch Clin Exp Ophthalmol 1996;234: 359-63.
17. Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol 2000;165:7323-9.
18. Hammer H. Lymphocyte transformation test in sympathetic ophthalmitis and the Vogt-Koyanagi-Harada syndrome. Br J Ophthalmol 1971;55:850-2.
19. Hammer H. Cellular hypersensitivity to uveal pigment confirmed by leucocyte migration tests in sympathetic ophthalmitis and the Vogt-Koyanagi-Harada syndrome. Br J Ophthalmol 1974;58:773-6.
20. Matsuda H, Sugiura S. Ultrastructural changes of the melanocyte in Vogt-Koyanagi-Harada syndrome and sympathetic ophthalmia. Jpn J Ophthamol 1971;15:69-80.
21. Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 2002;71:565-81.
22. Dumoulin FL, Leifeld L, Saucerbrunch T, Spengler U. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother 1999;53:242-54.
23. Imagawa A, Itoh N, Hanafusa T, Oda Y, Waguri M, Miyagawa J, et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab 1995;80:922-6.
24. Bosi E, Minelli R, Bazzigaluppi E, Salvi M. Fulminant autoimmune type I diabetes during interferon-alpha therapy: A case of Th1-mediated disease? Diabet Med 2001;18:329-33.
25. Downs AM, Dunnill MG. Exacerbation of psoriasis by interferon-alpha therapy for chronic hepatitis C. Clin Exp Dermatol 200;25:351-2.
26. Passos de Souza E, Evangelista Segundo PT, Jose FF, Lemaire D, Santigo M. Rheumatoid arthritis induced by alpha-interferon therapy. Clin Rheumatol 2001;20:297-9.
27. Budak-Alpdogan T, Demircay Z, Alpdogan O, Direskeneli H, Ergun T, Bayik M, et al. Behcet's disease in patients with chronic myelogenous leukemia: Possible role of interferon-alpha treatment in the occurrence of Behcet's symptoms. Ann Hematol 1997;74:45-8.
28. Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight-threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423-31.